BOSTON and LONDON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on developing transformational medicines, today ...
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 ...
Alkermes announced today the initiation of the Brilliance Studies, a phase 3 program that will test the safety and efficacy ...
PLYMOUTH MEETING, PA — Harmony Biosciences recently revealed compelling preclinical data for BP1.15205, a highly potent and selective orexin 2 receptor (OX2R) agonist, at the 39th Annual Meeting of ...
BOSTON and LONDON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (CNTA), a clinical-stage pharmaceutical company, today announced that its Board of Directors has appointed Mario ...
Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best biotech stocks to invest in now. On June 16, Centessa Pharmaceuticals announced that the US FDA cleared its Investigational New Drug/IND ...
Eli Lilly agreed to acquire Centessa Pharmaceuticals for approximately $7.8 billion, expanding its neuroscience pipeline. Eli ...
Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best biotech stocks to invest in now. On June 16, Centessa Pharmaceuticals announced that the US FDA cleared its Investigational New Drug/IND ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results